LeonaBio's Series A warrants become exercisable, could raise $146.2 million

LeonaBio, Inc. disclosed in an 8-K dated September 18, 2026 that warrants tied to a prior private placement have become exercisable.

In December 2025, as part of a private placement, the company issued warrants to purchase an aggregate of 23,031,494 shares of its common stock, called the Series A Common Warrants.¹ The warrants carry an exercise price of $6.35 per share.¹

The warrants became exercisable on September 18, 2026 and will remain exercisable through October 19, 2026, under their original terms.¹ If all warrant holders exercise for cash, LeonaBio said it would receive approximately $146.2 million in additional capital.¹

The company cautioned that this outcome is not guaranteed. LeonaBio noted risks that could cause actual results to differ, including the possibility that some or all of the warrants expire without being exercised, or that holders instead choose a cashless net exercise if the resale registration statement covering the underlying shares is not effective at the time, either of which would reduce or eliminate cash proceeds to the company.¹

The filing was signed by Mark Litton, President and Chief Executive Officer, and dated September 22, 2026. LeonaBio said the forward-looking statements in the filing speak only as of the date of the report, and the company does not plan to update them except as required by law.¹